Antiplasmodial activity of chloroquine analogs against chloroquine-resistant parasites, docking studies and mechanisms of drug action

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  De Souza, Nicolli B ^a   Carmo, Arturene M L ^b   Da Silva, Adilson D ^b   França, Tanos C C ^c   Krettli, Antoniana U ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

^c MILITARY INSTITUTE OF ENGINEERING   (Brazil)

Author keywords

Chloroquine analogs; Diaminealkyne; Diaminedialkyne; Docking; Lactate dehydrogenase enzyme; Malaria; P. falciparum

Indexed keywords

CHLOROQUINE; LACTATE DEHYDROGENASE; ANTIMALARIAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL DRUG RESISTANCE; ANTIPLASMODIAL ACTIVITY; ARTICLE; BIOASSAY; CONTROLLED STUDY; CRYSTALLIZATION; DRUG ACTIVITY; DRUG CONFORMATION; DRUG MECHANISM; DRUG SELECTIVITY INDEX; DRUG STRUCTURE; ENZYME INHIBITION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HYDROGEN BOND; IC50; IN VITRO STUDY; MOLECULAR DOCKING; MOUSE; NONHUMAN; PARASITEMIA; PHARMACOLOGICAL PARAMETERS; PLASMODIUM BERGHEI; PLASMODIUM BERGHEI INFECTION; PLASMODIUM FALCIPARUM; STRUCTURE ACTIVITY RELATION; ANALOGS AND DERIVATIVES; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SENSITIVITY; LIVER CELL; PHYSIOLOGY;

ANTIMALARIALS; CELL SURVIVAL; CHLOROQUINE; DRUG RESISTANCE; HEPATOCYTES; INHIBITORY CONCENTRATION 50; MOLECULAR DOCKING SIMULATION; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84989237215     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-469     Document Type: Article

References (59)

1. WHO: World Malaria Report 2013. Geneva: World Health Organization; 2014. http://www.who.int/malaria/publications/world-malaria-report-2013/report/en/.
2. WHO: Guidelines for Treatment of Human Malaria. 2nd edition. Geneva: World Health Organization; 2010.
3. WHO: Global Report on Antimalarial Drug Efficacy and Drug Resistance 2000-2010. Geneva: World Health Organization; 2010.
4. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ: Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009, 361:455-457.
5. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, ler Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day NP, White NJ, Anderson TJ, Nosten F: Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012, 379:1960-1966.
6. Miotto O, Almagro-Garcia J, Manske M, Macinnis B, Campino S, Rockett KA, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Duong S, Nguon C, Chuor CM, Saunders D, Se Y, Lon C, Fukuda MM, Amenga-Etego L, Hodgson AV, Asoala V, Imwong M, Takala-Harrison S, Nosten F, Su XZ, Ringwald P, Ariey F, Dolecek C, Hien TT, Boni MF, et al: Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet 2013, 45:648-655.
7. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, Sidhu AB, Naudé B, Deitsch KW, Su XZ, Wootton JC, Roepe PD, Wellems TE: Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 2000, 6:861-871.
8. Roepe PD: PfCRT-mediated drug transport in malarial parasites. Biochemistry 2011, 50:163-171.
9. Price RN, Douglas NM, Anstey NM: New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis 2009, 22:430-435.
10. Graf PC, Durand S, Alvarez Antonio C, Montalvan C, Galves Montoya M, Green MD, Santolalla ML, Salas C, Lucas C, Bacon DJ, Fryauff DJ: Failure of supervised chloroquine and primaquine regimen for the treatment of Plasmodium vivax in the Peruvian Amazon. Malar Res Treat 2012, 2012:936067.
11. Gama BE, Lacerda MVG, Daniel-Ribeiro CT, Ferreira-da-Cruz MDF: Chemore-sistance of Plasmodium falciparum and Plasmodium vivax parasites in Brazil: consequences on disease morbidity and control. Mem Inst Oswaldo Cruz 2011, 106:159-166.
12. Aguiar AC, Pereira DB, Amaral NS, De Marco L, Krettli AU: Plasmodium vivax and Plasmodium falciparum ex vivo susceptibility to anti-malarials and gene characterization in Rondônia, West Amazon, Brazil. Malar J 2014, 13:73.
13. Hocart SJ, Liu H, Deng H, De D, Krogstad FM: 4-aminoquinolines active against chloroquine-resistant Plasmodium falciparum: basis of antiparasite activity and quantitative structure-activity relationship analyses. Antimicrob Agents Chemother 2011, 55:2233-2244.
14. Casagrande M, Barteselli A, Basilico N, Parapini S, Taramelli D, Sparatore A: Synthesis and antiplasmodial activity of new heteroaryl derivatives of 7-chloro-4-aminoquinoline. Bioorg Med Chem 2012, 20:5965-5979.
15. Stocks PA, Raynes KJ, Bray PG, Park BK, O'Neill PM, Ward SA: Novel short chain chloroquine analogues retain activity against chloroquine resistant K1 Plasmodium falciparum. J Med Chem 2002, 45:4975-4983.
16. Solomon VR, Puri SK, Srivastava K, Katti SB: Design and synthesis of new antimalarial agents from 4-aminoquinoline. Bioorg Med Chem 2005, 33:2165.
17. Cunico W, Cechinel CA, Bonacorso HG, Martins MAP, Zanatta N, de Souza MVN, Freitas IO, Soares RPP, Krettli AU: Antimalarial activity of 4-(5-trifluor-omethyl-1H-pyrazol-1-yl)-chloroquine analogues. Bioorg Med Chem Lett 2006, 16:649-653.
18. Madrid PB, Wilson NT, DeRisi JL, Guy RK: Parallel synthesis and antimalarial screening of a 4-aminoquinoline library. J Comb Chem 2004, 6:437-442.
19. de Souza NB, Carmo AM, Lagatta DC, Alves MJ, Fontes AP, Coimbra ES, da Silva AD, Abramo C: 4-aminoquinoline analogues and its platinum (II) complexes as antimalarial agents. Biomed Pharmacother 2011, 65:313-316.
20. Read JA, Wilkinson KW, Tranter R, Sessions RB, Brady RL: Chloroquine binds in the cofactor binding site of Plasmodium falciparum lactate dehydrogenase. J Biol Chem 1999, 274:10213-10218.
21. Cortopassi WA, Oliveira AA, Guimarães AP, Rennó MN, Krettli AU, França TC: Docking studies on the binding of quinoline derivatives and hematin to Plasmodium falciparum lactate dehydrogenase. J Biomol Struct Dyn 2011, 29:207-218.
22. Carmo AM, Silva FM, Machado PA, Fontes AP, Pavan FR, Leite CQ, Leite SR, Coimbra ES, Da Silva AD: Synthesis of 4-aminoquinoline analogues and their platinum(II) complexes as new antileishmanial and antitubercular agents. Biomed Pharmacother 2011, 65:204-209.
23. Denizot F, Lang R: Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986, 89:271-277.
24. do Céu de Madureira M, Paula Martins A, Gomes M, Paiva J, Proença da Cunha A, do Rosário V: Antimalarial activity of medicinal plants used in traditional medicine in S Tomé and Príncipe islands. J Ethnopharmacol 2002, 81:23-29.
25. Oduola AM, Milhous WK, Weatherly NF, Bowdre JH, Desjardins RE: Plasmodium falciparum: induction of resistance to mefloquine in cloned strains by continuous drug exposure in vitro. Exp Parasitol 1988, 67:354-360.
26. Trager W, Jensen JB: Human malaria parasites in continuous culture. Science 1976, 193:673-675.
27. Lambros C, Vanderberg JP: Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol 1979, 65:418-420.
28. Rieckmann KH, Campbell GH, Sax LJ, Mrema JE: Drug sensitivity of Plasmodium falciparum. An in vitro microtechnique. Lancet 1978, i:22-23.
29. Noedl H, Wongsrichanalai C, Miller RS, Myint KS, Looareesuwan S, Sukthana Y, Wongchotigul V, Kollaritsch H, Wiedermann G, Wernsdorfer WH: Plasmodium falciparum: effect of anti-malarial drugs on the production and secretion characteristics of histidine-rich protein II. Exp Parasitol 2002, 102:157-163.
30. Peters W, Portus JH, Robinson BL: The four-day suppressive in vivo antimalarial test. Ann Trop Med Parasitol 1975, 69:155-171.
31. Andrade-Neto VF, Goulart MFO, Silva-Filho JF, Matusalém JS, Pinto MCFR, Pinto AV, Zalis MG, Carvalho LH, Krettli AU: Antimalarial activity of phena-zines from lapachol, β-lapachone and its derivatives against Plasmodium falciparum in vitro and Plasmodium berghei in vivo. Bioorg Med Chem Lett 2004, 14:1145-1149.
32. Krettli AU, Pereira JP, Brener Z: Comparative study of experimental infections in mice inoculated with normal and chloroquine-resistant strains of Plasmodium berghei. Rev Inst Med Trop Sao Paulo 1969, 11:94-100.
33. Pisciotta JM, Coppens I, Tripathi AK, Scholl PF, Shuman J, Bajad S, Shulaev V, Sullivan DJ Jr: The role of neutral lipid nanospheres in Plasmodium falciparum haem crystallization. Biochem J 2007, 402:197-204.
34. Hehre WJ: A Guide to Molecular Mechanics and Quantum Chemical Calculations. Irvine: Wavefunction, Inc; 2003.
35. Halgren TA: Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem 1996, 17:490-519.
36. Rocha GB, Freire RO, Simas AM, Stewart JJ: RM1: a reparameterization of AM1 for H, C, N, O, P, S, F, Cl, Br, and I. J Comput Chem 2006, 27:1101-1111.
37. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The protein data bank. Nucl Acids Res 2000, 28:235-242.
38. Thomsen R, Christensen MH: MolDock: a new technique for high-accuracy molecular docking. J Med Chem 2006, 49:3315-3321.
39. Gligorijevic B, Purdy K, Elliott DA, Cooper RA, Roepe PD: Stage independent chloroquine resistance and chloroquine toxicity revealed via spinning disk confocal microscopy. Mol Biochem Parasitol 2008, 159:7-23.
40. Solomon VR, Haq W, Srivastava K, Puri SK, Katti SB: Synthesis and antimalarial activity of side chain modified 4-aminoquinoline derivatives. J Med Chem 2007, 50:394-398.
41. Solaja BA, Opsenica D, Smith KS, Milhous WK, Terzic N, Opsenica I, Burnett JC, Nuss J, Gussio R, Bavari S: Novel 4-aminoquinolines active against chloroquine-resistant and sensitive P. falciparum strains that also inhibit botulinum serotype A. J Med Chem 2008, 51:4388-4391.
42. Wenzel NI, Chavain N, Wang Y, Friebolin W, Maes L, Pradines B, Lanzer M, Yardley V, Brun R, Herold-Mende C, Biot C, Tóth K, Davioud-Charvet E: Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA. J Med Chem 2010, 53:3214-3226.
43. Iwaniuk DP, Whetmore ED, Rosa N, Ekoue-Kovi K, Alumasa J, de Dios AC, Roepe PD, Wolf C: Synthesis and antimalarial activity of new chloroquine analogues carrying a multifunctional linear side chain. Bioorg Med Chem 2009, 17:6560-6566.
44. Egan TJ, Ncokazi KK: Quinoline antimalarials decrease the rate of β-hematin formation. J Inorg Biochem 2005, 99:1532-1539.
45. Kontoyianni M, McClellan LM, Sokol GS: Evaluation of docking performance: comparative data on docking algorithms. J Med Chem 2004, 47:558-565.
46. Leach AR, Shoichet BK, Peishof CE: Prediction of protein-ligand interactions. Docking and scoring: Successes and gaps. J Med Chem 2006, 49:5851-5855.
47. Warren GL, Andrews CW, Capelli AM, Clarke B, LaLonde J, Lambert MH, Lindvall M, Nevins N, Semus SF, Senger S, Tedesco G, Wall ID, Woolven JM, Peishoff CE, Head MS: A critical assessment of docking programs and scoring functions. J Med Chem 2006, 49:5912-5931.
48. Uren AG, O'Rourke K, Aravind LA, Pisabarro MT, Seshagiri S, Koonin EV, Dixit VM: Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol Cell 2000, 6:961-967.
49. Meslin B, Barnadas C, Boni V, Latour C, De Monbrison F, Kaiser K, Picot S: Features of apoptosis in Plasmodium falciparum erythrocytic stage through a putative role of PfMCA1 metacaspase-like protein. J Infect Dis 2007, 195:1852-1859.
50. Kitamura K, Kishi-Itakura C, Tsuboi T, Sato S, Kita K, Ohta N, Mizushima N: Autophagy-related Atg8 localizes to the apicoplast of the human malaria parasite Plasmodium falciparum. PLoS One 2012, 7:e42977.
51. Walker DM, Mahfooz N, Kemme KA, Patel VC, Spangler M, Drew ME: Plasmodium falciparum erythrocytic stage parasites require the putative autophagy protein PfAtg7 for normal growth. PLoS One 2013, 8:e67047.
52. Totino PR, Daniel-Ribeiro CT, Corte-Real S, de Fátima F-d-C M: Plasmodium falciparum: erythrocytic stages die by autophagic-like cell death under drug pressure. Exp Parasitol 2008, 118:478-486.
53. Bursch W: The autophagosomal-lysosomal compartment in programmed cell death. Cell Death Differ 2001, 8:569-581.
54. Rijpma SR, van den Heuvel JJ, van der Velden M, Sauerwein RW, Russel FG, Koenderink JB: Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity. Malar J 2014, 13:359.
55. Nogueira F, Lopes D, Alves AC, do Rosário VE: Plasmodium falciparum multidrug resistance protein (MRP) gene expression under chloroquine and mefloquine challenge. J Cell An Biol 2008, 2:010-020.
56. Zishiri VK, Joshi MC, Hunter R, Chibale K, Smith PJ, Summers RL, Martin RE, Egan TJ: Quinoline antimalarials containing a dibemethin group are active against chloroquinone-resistant Plasmodium falciparum and inhibit chloroquine transport via the P. falciparum chloroquine-resistance transporter (PfCRT). J Med Chem 2011, 54:6956-6968.
57. Ghobakhloo N, Nateghpour M, Rezaee S, Hajjaran H, Mohebali M, Abedkhojasteh H: Variation of the chloroquine resistance transporter (Crt) gene in chloroquine-resistant and chloroquine-sensitive Plasmodium berghei. Iran J Parasitol 2008, 3:39-44.
58. Frosch AE, Laufer MK, Mathanga DP, Takala-Harrison S, Skarbinski J, Claassen CW, Dzinjalamala FK, Plowe CV: Return of widespread chloroquine-sensitive Plasmodium falciparum to Malawi. J Infect Dis 2014, 210:1110-1114.
59. WHO: AFR E: Cost Effectiveness Results for Malaria. 2010. Available at http://www.who.int/choice/results/mal-afre/en/.